1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Drugs In Development, 2022, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 37, 21, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 3 molecules, respectively.
Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Merkel Cell Carcinoma - Overview
- Merkel Cell Carcinoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Merkel Cell Carcinoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Merkel Cell Carcinoma - Companies Involved in Therapeutics Development
- Merkel Cell Carcinoma - Drug Profiles
- Merkel Cell Carcinoma - Dormant Projects
- Merkel Cell Carcinoma - Discontinued Products
- Merkel Cell Carcinoma - Product Development Milestones
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Merkel Cell Carcinoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..2)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Merkel Cell Carcinoma - Dormant Projects, 2022
- Merkel Cell Carcinoma - Discontinued Products, 2022
- Number of Products under Development for Merkel Cell Carcinoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Affini-T Therapeutics Inc
- Aileron Therapeutics Inc
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Amgen Inc
- Apcure SAS
- Arcus Biosciences Inc
- Aulos Bioscience Inc
- Bavarian Nordic AS
- BeiGene Ltd
- Beijing Advaccine Biotechnology Company Ltd
- BeyondSpring Inc
- BioInvent International AB
- Biosion Inc
- Boston Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- CanWell Pharma Inc
- Centrymed Pharmaceutical Inc
- Checkpoint Therapeutics Inc
- Codiak BioSciences Inc
- CStone Pharmaceuticals Co Ltd
- CytomX Therapeutics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Exelixis Inc
- F-star Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fujifilm Holdings Corp
- Genexine Inc
- GI Innovation Co Ltd
- Guangzhou Yinming Biomedical Technology Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- ImmunityBio Inc
- Immunomic Therapeutics Inc
- Incyte Corp
- JSR Life Sciences LLC
- Kartos Therapeutics Inc
- Medicenna Therapeutics Corp
- Memgen Inc
- Merck & Co Inc
- Merck KGaA
- Morphogenesis Inc
- Novartis AG
- Ocellaris Pharma Inc
- OncoSec Medical Inc
- Oncovir Inc
- Ono Pharmaceutical Co Ltd
- Pfizer Inc
- Philogen SpA
- PokeAcell
- QBiotics Group Ltd
- Regeneron Pharmaceuticals Inc
- Replimune Ltd
- Seven and Eight Biopharmaceuticals Corp
- Simcha Therapeutics Inc
- SOTIO Biotech AS
- Tarveda Therapeutics Inc
- Treadwell Therapeutics Inc
